- Home
- KPTI vs ABVC Comparison
KPTI vs ABVC Comparison
Compare KPTI & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- ABVC
- Stock Information
- Founded
- KPTI 2008
- ABVC 2015
- Country
- KPTI United States
- ABVC United States
- Employees
- KPTI N/A
- ABVC N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- KPTI Health Care
- ABVC Health Care
- Exchange
- KPTI Nasdaq
- ABVC Nasdaq
- Market Cap
- KPTI 44.5M
- ABVC 52.1M
- IPO Year
- KPTI 2013
- ABVC N/A
- Fundamental
- Price
- KPTI $4.35
- ABVC $3.01
- Analyst Decision
- KPTI Buy
- ABVC
- Analyst Count
- KPTI 7
- ABVC 0
- Target Price
- KPTI $48.50
- ABVC N/A
- AVG Volume (30 Days)
- KPTI 225.6K
- ABVC 729.3K
- Earning Date
- KPTI 08-05-2025
- ABVC 08-13-2025
- Dividend Yield
- KPTI N/A
- ABVC N/A
- EPS Growth
- KPTI N/A
- ABVC N/A
- EPS
- KPTI N/A
- ABVC N/A
- Revenue
- KPTI $142,126,000.00
- ABVC $508,383.00
- Revenue This Year
- KPTI $2.09
- ABVC $735.18
- Revenue Next Year
- KPTI $12.90
- ABVC N/A
- P/E Ratio
- KPTI N/A
- ABVC N/A
- Revenue Growth
- KPTI 1.19
- ABVC 1904.43
- 52 Week Low
- KPTI $3.51
- ABVC $0.40
- 52 Week High
- KPTI $16.95
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- KPTI 48.87
- ABVC 50.14
- Support Level
- KPTI $3.84
- ABVC $2.91
- Resistance Level
- KPTI $4.91
- ABVC $3.39
- Average True Range (ATR)
- KPTI 0.48
- ABVC 0.58
- MACD
- KPTI 0.02
- ABVC -0.14
- Stochastic Oscillator
- KPTI 45.25
- ABVC 3.89
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.